Hemostemix Inc.
HEM
주식 순위
#32560
Hemostemix Inc., a clinical stage biotechnology company, develops,... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
주가
$0.04268108
마지막 동기화: 2026-10-21
시가총액
$9.02M
변동 (1일)
5.73%
변동 (1년)
-42.09%
국가
CA
거래 Hemostemix Inc. (HEM)
카테고리
Healthcare
Hemostemix Inc. (HEM)의 주가 이력
최고 종가: $0.04 (2026-10-01 기준)
최저 종가: $0.00 (2005-11-01 기준)
최저 종가: $0.00 (2005-11-01 기준)
Hemostemix Inc.의 주가 이력 (2005 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2026 (TTM) | -11.95% |
| 2025 | 20.30% |
| 2024 | -2.01% |
| 2023 | -53.19% |
| 2022 | -8.06% |
| 2021 | 925.13% |
| 2020 | 7.84% |
| 2019 | -99.16% |
| 2018 | 984,477.83% |
| 2017 | 242.51% |
| 2016 | -91.14% |
| 2015 | 0.00% |
| 2014 | 0.00% |
| 2013 | 0.00% |
| 2012 | 0.00% |
| 2011 | 0.00% |
| 2010 | -1.41% |
| 2009 | -34.26% |
| 2008 | -72.09% |
| 2007 | 17.99% |
| 2006 | 72.63% |
| 2005 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $760.15 | 8.04% |
CH
|
